L'Oréal is set to acquire an additional 10% stake in Galderma, boosting its investment in the dermatology leader to 20%, aimed at fostering collaboration in scientific research and product innovation.
Information on the Target
Galderma Group AG (SIX:GALD) is a leading company in dermatology, recognized for its commitment to innovation and science-based solutions. Established in 1981, Galderma operates in approximately 90 countries, offering a diverse range of premium brands and services. The company has established itself as the pure-play leader in the dermatology sector, focusing on Injectable Aesthetics, Dermatological Skincare, and Therapeutic Dermatology. With a mission to enhance skin health, Galderma addresses the unique needs of consumers and healthcare professionals alike.
In a significant development, Galderma announced on December 8, 2025, that L’Oréal Groupe will increase its equity investment by acquiring an additional 10% stake from Sunshine SwissCo GmbH, a consortium led by EQT, ADIA, and Auba Investment Pte. Ltd. This transaction, contingent upon customary approvals, will elevate L’Oréal's total stake in Galderma to 20%, building upon an initial investment made in August 2024.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview in Switzerland
The dermatology and beauty industry in Switzerland is experiencing rapid growth, reflective of broader global trends. Increased public awareness of skin health, aging populations, and rising disposable incomes
Similar Deals
Prime Healthcare Foundation → Central Maine Healthcare
2025
L’Oréal Groupe
invested in
Galderma Group AG
in 2025
in a Corporate VC deal